๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome

โœ Scribed by Kumar-singh, Samir; Jacobs, Werner; Dhaene, Karl; Weyn, Barbara; Bogers, Johannes; Weyler, Joost; Marck, Eric Van


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
299 KB
Volume
186
Category
Article
ISSN
0022-3417

No coin nor oath required. For personal study only.

โœฆ Synopsis


Syndecan-1 binds basic fibroblast growth factor (bFGF), modulates neovascularization, plays a role in epithelial differentiation and is up-regulated by WT1. Malignant mesothelioma of the pleura is one of the most aggressive tumours known and expresses high levels of angiogenic growth factors. This study has analysed syndecan-1 expression in mesothelioma tumours and cell lines by immunohistochemistry and immunoblotting, using anti-syndecan-1 antibody directed against the core protein, and has examined its relation to morphology, bFGF, WT1, and intra-tumoural microvascular density (IMD). Shedding of syndecan-1 in the conditioned medium of mesothelioma cell lines was detected in variable amounts. These studies indicate that (1) there is no correlation of syndecan-1 with either bFGF expression or IMD in mesotheliomas in vivo; (2) syndecan-1 is strongly expressed in the epithelial type of mesothelioma and in the epithelial component of biphasic mesotheliomas and the expression is reduced or lost in sarcomatoid differentiation; together with the finding that (3) syndecan-1 correlates with WT1 immuno-expression, this suggests that syndecan-1 might relate to the differentiation state of mesothelial/mesothelioma cells; and (4) syndecan-1-positive tumours are associated with a longer survival (p = 0.02) than mesotheliomas with no or little syndecan-1 expression, on univariate analysis. These findings therefore indicate that syndecan-1 can be an important prognostic indicator in mesotheliomas and its loss may be important in the epithelial-mesenchymal transformation of mesothelioma cells.


๐Ÿ“œ SIMILAR VOLUMES


Thrombospondin-1 expression and clinical
โœ Yasuhiko Ohta; Viji Shridhar; Gregory P. Kalemkerian; Robert K. Bright; Yoh Wata ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 2 views

## BACKGROUND. The role of thrombospondin-1 (TSP-1) in tumor angiogenesis and progression is controversial. The authors assessed the impact of TSP-1 as a prognostic indicator in malignant pleural mesothelioma (MPM). ## METHODS. TSP-1 expression was assessed by reverse transcriptase-polymerase c

nm23-H1 expression in nasopharyngeal car
โœ Xiang Guo; Hua-qing Min; Mu-sheng Zeng; Chao-nan Qian; Xiao-ming Huang; Jian-yon ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 148 KB

The expression levels of nm23-H1 mRNA and its protein in human nasopharyngeal carcinoma (NPC) were detected to clarify the relationship between nm23-H1 and metastasis and prognosis of patients with NPC. nm23-H1 mRNA expression in fresh tissues from 78 patients with NPC was investigated by in situ hy

Co-ordinated over-expression of the MRP
โœ Besim Ogretmen; Hamid R. Bahadori; Mary D. McCauley; Alice Boylan; Mark R. Green ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 84 KB ๐Ÿ‘ 1 views

While human malignant mesothelioma is extremely resistant to chemotherapy, its intrinsic resistance mechanisms remain largely unknown. In this study, we used normal human mesothelial cells and 5 human mesothelioma cell lines not previously exposed to chemotherapeutic agents to demonstrate that the m

Expression of transporter associated wit
โœ Per Thor Straten; Alexei F. Kirkin; Tina Seremet; Jesper Zeuthen ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 108 KB ๐Ÿ‘ 1 views

TAP1 and TAP2 molecules are involved in the transport of peptides prior to their association with class I molecules and are mandatory for efficient antigen presentation. To investigate whether loss of expression of TAP1 or TAP2 is a likely mechanism of immune escape in malignant melanoma, TAP1 and T